Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

Lina van der Straten; Avinash G. Dinmohamed; Peter E. Westerweel; Anton W. Langerak; Jurgen Riedl; Jeanette K. Doorduijn; Arnon P. Kater; Mark-David Levin

doi:https://doi.org/10.1080/10428194.2018.1452215

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

Lina van der Straten, Avinash G. Dinmohamed, Peter E. Westerweel, Anton W. Langerak, Jurgen Riedl, Jeanette K. Doorduijn, Arnon P. Kater, Mark-David Levin

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	2757-2761
Journal	Leukemia & lymphoma
Volume	59
Issue number	11
Early online date	5 Apr 2018
DOIs	https://doi.org/10.1080/10428194.2018.1452215
Publication status	Published - Nov 2018

Access to Document

https://doi.org/10.1080/10428194.2018.1452215

Cite this

van der Straten, L., Dinmohamed, A. G., Westerweel, P. E., Langerak, A. W., Riedl, J., Doorduijn, J. K., Kater, A. P., & Levin, M.-D. (2018). Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia & lymphoma, 59(11), 2757-2761. https://doi.org/10.1080/10428194.2018.1452215

@article{9c8b3b301b0b4a52a1aa4bdbb62dda9b,

title = "Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy",

author = "{van der Straten}, Lina and Dinmohamed, {Avinash G.} and Westerweel, {Peter E.} and Langerak, {Anton W.} and Jurgen Riedl and Doorduijn, {Jeanette K.} and Kater, {Arnon P.} and Mark-David Levin",

year = "2018",

month = nov,

doi = "https://doi.org/10.1080/10428194.2018.1452215",

language = "English",

volume = "59",

pages = "2757--2761",

journal = "Leukemia & lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

van der Straten, L, Dinmohamed, AG, Westerweel, PE, Langerak, AW, Riedl, J, Doorduijn, JK, Kater, AP & Levin, M-D 2018, 'Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy', Leukemia & lymphoma, vol. 59, no. 11, pp. 2757-2761. https://doi.org/10.1080/10428194.2018.1452215

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. / van der Straten, Lina; Dinmohamed, Avinash G.; Westerweel, Peter E. et al.
In: Leukemia & lymphoma, Vol. 59, No. 11, 11.2018, p. 2757-2761.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

AU - van der Straten, Lina

AU - Dinmohamed, Avinash G.

AU - Westerweel, Peter E.

AU - Langerak, Anton W.

AU - Riedl, Jurgen

AU - Doorduijn, Jeanette K.

AU - Kater, Arnon P.

AU - Levin, Mark-David

PY - 2018/11

Y1 - 2018/11

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044932859&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29616852

U2 - https://doi.org/10.1080/10428194.2018.1452215

DO - https://doi.org/10.1080/10428194.2018.1452215

M3 - Article

C2 - 29616852

SN - 1042-8194

VL - 59

SP - 2757

EP - 2761

JO - Leukemia & lymphoma

JF - Leukemia & lymphoma

IS - 11

ER -

van der Straten L, Dinmohamed AG, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK et al. Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia & lymphoma. 2018 Nov;59(11):2757-2761. Epub 2018 Apr 5. doi: https://doi.org/10.1080/10428194.2018.1452215

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

Access to Document

Other files and links

Cite this